The news of RBC Capital maintaining an Outperform rating and raising the price target for Legend Biotech (LEGN) is positive for the stock. This indicates that the analyst believes the company's stock will outperform the market, and the increased price target suggests a higher potential upside. This is likely to have a positive short-term impact on LEGN's stock price.